Another large study of patients receiving immunotherapy, this time a secondary analysis of 665 patients prospectively receiving nivolumab for metastatic renal cell carcinoma, confirms no detriment in survival when patients require concurrent corticosteroids. In fact, patients who received steroids actually had longer survival than those who didn’t. | Lefort, JAMA Oncol 2023
